#USA #Orlando #Nordic Pharma #LACRIFILL #Dry Eye

Nordic Group B.V. Highlights LACRIFILL® at AAO 2025

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is set to present groundbreaking findings on LACRIFILL® Canalicular Gel, a novel therapy targeting dry eye symptoms. This event will take place at the Annual Meeting of the American Academy of Ophthalmology (AAO) in Orlando, Florida, from October 18 to 20, 2025. Nordic will dive into patient data and recent studies regarding patient experience with LACRIFILL®, aiming to enlighten ophthalmic professionals regarding its benefits.

Dr. Jai Parekh, MBA, the Commercial Director of Eye Care U.S., expressed excitement over the data presented: "We are thrilled that 98.11% of surveyed patients, both new and repeat users of LACRIFILL® Canalicular Gel, affirmed they would choose to return for another dose. This speaks volumes about the product's efficacy and patient satisfaction."

The symposium at AAO aims not just to showcase innovative therapies, but also to gather insights from leading professionals in the field. Dr. Vance Thompson, alongside Dr. Kayla Karpuk and Dr. Mark Packer, has been invited as co-authors for an upcoming 'Critical Perspectives' article on lacrimal occlusion within the context of cataract and refractive surgery, set to be published in the Expert Review of Ophthalmology. Dr. Thompson noted the significant impact of dry eye disease on preoperative planning and overall patient satisfaction: "LACRIFILL® addresses niche requirements as it’s indicated for use up to six months, thus enhancing preoperative ocular surface condition and maintaining postoperative benefits."

On October 18 at 5:30 PM, Nordic Pharma is proud to sponsor the Women in Ophthalmology (WIO) Networking Reception and Awards Ceremony, a testament to their commitment to fostering diversity within the field. Lisa M. Nijm, MD, JD, CEO of WIO and founder of Warrenville Eyecare Lasik, acknowledged Nordic Pharma's ongoing support for honoring outstanding women in ophthalmology.

AAO attendees are encouraged to explore Booth #1401 for live demonstrations of injections and to place orders. Furthermore, the recent TFOS Dry Eye Workshop (DEWS) III report published in the American Journal of Ophthalmology highlighted two studies regarding Nordic Pharma's new reticulated hyaluronic acid (AH) canalicular filler within Section 6.2.4, 'New Designs for Plugs and Other Technologies.' One study reported significant improvements in corneal staining, Schirmer testing scores, and other metrics three months post-administration. Another study compared LACRIFILL® Canalicular Gel to a commercially available hydrogel plug and concluded that the reticulated AH filler was both safe and well tolerated while maintaining statistically significant improvements in dry eye disease signs and symptoms over a six-month period.

For more details and ordering information regarding LACRIFILL® Canalicular Gel, please visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is an international, privately-owned mid-size pharmaceutical company focused on the development and commercialization of specialized products. The company has enhanced its portfolio through targeted developments and acquisitions to solidify its footing in ocular care, rheumatology, and women's health. With a robust presence across Europe, Nordic Group has expanded its operations globally through strategic acquisitions.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. partners with established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology-derived medicines, sterile manufacturing, and advanced technologies to market.

Forward-Looking Statements

This press release contains forward-looking statements, including those related to Nordic Group/Nordic Pharma's commercial development and strategic initiatives. These statements reflect the current opinions, expectations, and beliefs of the company regarding future events, which involve risks and uncertainties that could cause actual developments and outcomes to differ significantly. Such factors include general market conditions, regulatory trends, and changes to third-party financial conditions that could impact commercial performance.

Contact Information

Nordic Pharma, Inc.
Kate Popova
Project and Contract Manager
Phone: 610-285-1699
Email: [email protected]

Gail Feerrar
Sales and Marketing Director
Phone: 610-285-7152
Email: [email protected]